1,544
Views
2
CrossRef citations to date
0
Altmetric
Research Article

The effects of oral calcium on the prevention of moderate to severe ovarian hyperstimulation syndrome in high-risk patients: A placebo-controlled study

, , & | (Reviewing editor)
Article: 1668212 | Received 14 Jan 2019, Accepted 08 Sep 2019, Published online: 26 Sep 2019

References

  • Saad, A.S & Smohamed, K. A. A. (2017). Calcium dobesilate versus cabergoline for prevention of Ovarian hyper stimulation syndrome. Reproductive System & Sexual Disorders: Current Research, 6(1), 1–10.
  • American Society for Reproductive medicine, Birmingham, Alabama. (2016). Prevention and treatment of moderate and sever ovarian hyperstimulion syndrome: A guidline. Fertility and Sterility, 106, 1634–1647. doi:10.1016/j.fertnstert.2016.08.048
  • Anand, V., Jenifer, M. B., & Williams, J. S. (2015). The renin-angiotensin-aldosterone system and calcium-regulatory hormones. Journal of Human Hypertension, 29(9), 515–521. doi:10.1038/jhh.2014.125
  • Antonipillai, I., & Horton, R. (1985). Role of extra- and intracellular calcium and calmodulin in renin release from isolated rat kidney. Endocrinology, 117, 601–606. doi:10.1210/endo-117-2-591
  • Atchison, D. K., Ortiz-Capisano, M. C., & Beierwaltes, W. H. (2010). Acute activation of the calcium-sensing receptor inhibits plasma renin activity in vivo. American Journal of Physiology Regulatory, Integrative and Comparative Physiology, 299(4), R1020–6. doi:10.1152/ajpregu.00238.2010
  • Beierwaltes, W. H. (2010). The role of calcium in the regulation of renin secretion. American Journal of Physiology. Renal Physiology, 298(1), F1–F11. doi:10.1152/ajprenal.00143.2009
  • Bergh, P. A., & Navot, D. (1992). Ovarian hyperstimulation syndrome: A review of pathophysiology. Journal of Assisted Reproduction and Genetics, 9, 429–438. doi:10.1007/bf01204048
  • El-Khayat, W., & Elsadek, M. (2015). Calcium infusion for the prevention of ovarian hyperstimulation syndrome: Adouble-blind randomized controlled trial. Fertility and Sterility, 103, 101–105. doi:10.1016/j.fertnstert.2014.09.046
  • Fábregues, F., Balasch, J., Gìnès, P., Manau, D., Jimènez, W., Arroyo, V., & Vanrell, J. A. (1999). Ascites ad liver test abnormalities during severe ovarian hyperstimulation syndrome. The American Journal of Gastroenterology, 94, 994–999. doi:10.1016/S0002-9270(99)00057-X
  • Fernandez, L. A., Tarlatzis, B. C., Rzasa, P. J., Caride, V. J., Laufer, N., Negro-Vilar, A. F., … & Naftolin, F. (1985). Renin-like activity in ovarian follicular fluid. Fertility and Sterility, 44, 219–223. doi:10.1016/S0015-0282(16)48740-6
  • Fray, J. C. S., Park, C. S., & Valentine, A. N. D. (1987). Calcium and the control of renin secretion. Endocrine Reviews, 8, 53–93. doi:10.1210/edrv-8-1-53
  • Geva, E., & Jaffe, R. B. (2000). Role of vascular endothelial growth factor in ovarian physiology and pathophysiology. Fertility and Sterility, 74, 429–438. doi:10.1016/S0015-0282(00)00670-1
  • Gurgan, T., Demirol, A., Guven, S., Benkhalifa, M., Girgin, B., & Li, T. C. (2011). Intravenous calcium infusion as a novel preventive therapy of ovarian hyperstimulation syndrome for patients with polycystic ovarian syndrome. Fertility and Sterility, 96, 53–57. doi:10.1016/j.fertnstert.2011.04.094
  • Home/Drugs A to Z/Calcium carbonate/Side Effects. (2018) . Retrieved from www.Drugs.com
  • Isaac, R., Raymond, J. P., Rainfray, M., & Ardaillou, R. (1984). Effects of an acute calcium load on plasma ACTH, cortisol, aldosterone and renin activity in man. Acta Endocrinologica, 105(2), 251–257. doi:10.1530/acta.0.1050251
  • Keeton, T. K., & Campbell, W. B. (1980). The pharmacologic alteration of renin release. Pharmacological Reviews, 32, 81–227.
  • luconate Injection. (2018). Retrieved from www.Drugs.com.Home/Professionals/FDAPI/Calcium
  • Manno, M., & Tome, I. F. (2008). Renin-angiotensin system activation during severe OHSS: Cause or effect? Fertility and Sterility, 89, 488. doi:10.1016/j.fertnstert.2007.02.059
  • Naredi, N., & Karunakaran, S. (2013). Calcium gluconate infusion is as effective as the vascular endothelial growth factor antagonist cabergoline for the prevention of ovarian hyrerstimulation syndrome. Journal of Reproductive Sciences, 6, 248–252. doi:10.4103/0974-1208.126293
  • Nastri, C. O., Ferriani, R. A., Rocha, I. A., & Martins, W. P. (2010). Ovarian hyperstimulation syndrome: Pathophysiology and prevention. Journal of Assisted Reproduction and Genetics, 27, 121–128. doi:10.1007/s10815-010-9387-6
  • Navot, D., Bergh, P. A., & Laufer, N. (1992). Ovarian hyperstimulation syndrome in novel reproductive technology: Prevention and treatment. Fertility and Sterility, 58, 249–261. doi:10.1016/s0015-0282(16)55188-7
  • Navot, D., Margalioth, E. J., Laufer, N., Birkenfeld, A., Relou, A., Rosler, A., & Schenker, J. G. (1987). Direct correlation between plasma renin activity and severity of the ovarian hyperstimulation syndrome. Fertility and Sterility, 48, 57–61. doi:10.1016/S0015-0282(16)59290-5
  • Pellicer, A., Albert, C., Mercader, A., Bonilla-Musoles, F., Remohi, J., & Simon, C. (1999). The pathogenesis of ovarian hyperstimulation syndrome: In vivo studies investigating the role of interlukin-1β, interlukine-6, and vascular endothelial growth factor. Fertility and Sterility, 71, 482–489. doi:10.1016/S0015-0282(98)00484-1
  • Practice Committee of American Society for Reproductive Medicine. (2016). Prevention and treatment of moderate to severe ovarian hyper stimulation syndrome: A guideline. Fertility and Strility, 106, 1634–1647. doi:10.1016/j.fertnstert.2016.08.048